Together, our study provides, to our knowledge, the first large-scale evaluation of GLP-1 analogs in people living with Alzheimer’s disease and provides an insight into the mechanism of action of GLP-1 analogs in neurodegenerative diseases. This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.